| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 |
| 06 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027, subject to regulatory feedback |
| 09 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Relay Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), |
| 21 May 2026 |
8-K: Entry into a Material Definitive Agreement
22,916,667 Shares of Common Stock, par value $0.001 per share |
| 19 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer |
| 27 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer |
| 16 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 |
| 11 Mar 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced |
| 03 Feb 2026 |
8-K: Regulation FD Disclosure; Other Events
Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer |
| 11 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Cambridge, Mass. – June 11, 2025 – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today ... |
| 06 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 6, 2025, Relay Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) to consider and vote on the three proposals set forth below, each of which is described in detail in the Compan... |
| 04 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
On June 3, 2025, Relay Therapeutics, Inc. (the “Company”) and ARE MA Region No. 58, LLC (the “Landlord”) entered into the Third Amendment (the “Lease Amendment”) to the Lease Agreement (the “Binney Street Lease”), dated November 12, 2019... |
| 05 May 2025 |
8-K: Results of Operations and Financial Condition
Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 |
| 26 Feb 2025 |
8-K: Results of Operations and Financial Condition
Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- advanced breast cancer |
| 13 Jan 2025 |
8-K: Regulation FD Disclosure
J.P. Morgan Conference Presentation January 2025 Exhibit 99.1 |
| 11 Dec 2024 |
8-K: Regulation FD Disclosure; Other Events
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival |
Loading...